TMP-SMX for treating non-HIV lung infection
Part of Infections, Lungs & breathing clinical trials.
This study looks at how well the antibiotic combination TMP-SMX works for treating a type of lung infection called Pneumocystis pneumonia in people who do not have HIV. If you have this infection and are starting TMP-SMX, the study will follow your progress to see how safe and effective this treatment is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a diagnosis of Pneumocystis pneumonia (a lung infection) that is not related to HIV
- You must be starting treatment with the antibiotic combination TMP-SMX as your first treatment for this infection
- You must not be pregnant or breastfeeding
- You must not have a severe allergy or known intolerance to TMP-SMX or similar sulfa drugs
- Your TMP-SMX must be at a normal dose (not too high) and you must have taken it for at least 3 days when you join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
This study compares a lower dose versus the standard dose of the antibiotic TMP-SMX (Bactrim) to prevent a type of lung infection (Pneumocystis pneumonia) after a kidney transplant. If you are eligible, you will receive either a lower or standard dose to see which works just as well with fewer side effects.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This trial tests whether giving a special antibiotic treatment to clear a common lung fungus (Pneumocystis jirovecii) can reduce how often COPD flare-ups happen. If you qualify, this might help you have fewer severe episodes.
This trial tests how long kidney transplant patients should take a common antibiotic (sulfamethoxazole) to prevent a lung infection called PJP. You may join if you are between 18 and 70 and have had a kidney transplant.
Hear when a new Pneumocystis Jirovecii Pneumonia in Non-HIV Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.